AUSTIN, TX -- June 6, 2017 -- Lung Therapeutics, Inc., a clinical stage pharmaceutical company developing novel therapeutics for niche, orphan drug indications in fibrosis, lung injury and...

Lung Therapeutics, Inc., a clinical stage pharmaceutical company focused on niche, orphan drug indications in lung injury and disease, announced the enrollment today of the first patient in a...

December 2, 2014 FDA Orphan Drug Designation gives Lung Therapeutics a seven-year US market exclusivity for LTI-01 in the treatment of empyema, typically a complication of pneumonia. LTI-01 is...

October 28, 2014 Lung Therapeutics closes $1,550,000 of its initial Series A Preferred Stock financing, with additional milestone-driven commitments totaling $2,750,000. AUSTIN, TX — October 28,...